DUBLIN, Sept. 26, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Alzheimer's Disease Drug Pipeline, Diagnostics and Biomarkers: New Developments, Growth Areas and Opportunities" report to their offering.
This report is a comprehensive analysis and market study of the drug development pipeline relating to Alzheimer's Disease, which has been analysed alongside commercially available or developmental minimally-invasive AD diagnostics and associated companies, and minimally-invasive AD biomarkers.
- An in-depth review of the current AD drug development pipeline and companies
- Commercial review of minimally-invasive AD diagnostic tests and companies
- A focused analysis of early-stage biomarkers identified in AD patient studies
AD Drug Pipeline
This report covers today's AD drug development pipeline, up until August 2014. Today, there are four FDA approved drugs for AD and 103 in the development pipeline. Of these, 11, 41, 30 and 21 candidates are at phase 3, phase 2, phase 1 and preclinical stages, respectively. Together, these drugs and drug candidates are represented by 78 companies, which are identified in this report. An analysis of these drugs and candidates in terms of molecule types shows that small molecules represent the major group (70% overall), followed by antibodies (8%), vaccines (7%) and others (15%). In terms of the general pharmacological targeting strategies, 34 (32%) of candidates are targeted around Abeta. This report provides a comprehensive and up-to-date review of the current AD drug development pipeline by company, developmental phase (Phase 3 to preclinical), pharmacological targeting mechanisms and other areas.
AD Minimally-Invasive Diagnostics
This report identifies 21 companies with (specifically) AD-related diagnostics tests, platforms and developments relating to minimally-invasive techniques and capabilities. These diagnostic capabilities are presented on a company-by-company basis, however this group does not include laboratory suppliers of technologies such as PCR, microarray, mass spectrometry, flow cytometry, immunoassay, which are used or are generally applicable to AD research and clinical testing. Companies with imaging technologies or other related specifically to tests on CSF (which requires invasive techniques) are also not included.
New and emerging developments relating to early-stage biomarkers of AD, presented in this report, are broadly classified into approximately 35 different 'groups', which indicate their biological associations or origins relating to this disease. Together, these areas embrace the current AD-biomarker landscape. Overall, more than 270 biomarkers have been identified (where multivariate panels of partially-defined species are identified as one biomarker) and these are further classified in terms of the molecular groups to which they below.
New and emerging developments relating to early-stage biomarkers of AD, presented in this report, are broadly classified into approximately 35 different 'groups', which indicate their biological associations or origins relating to this disease. Overall, more than 270 biomarkers have been identified (where multivariate panels of partially-defined species are identified as one biomarker) and these are further classified in terms of the molecular groups to which they below.
Key Topics Covered:
Chapter 1. Background
Chapter 2. AD Drug Pipeline
Chapter 3. Diagnostics Companies of Minimally-Invasive AD Diagnostics
Chapter 4. AD Biomarkers
Chapter 5. Conclusions and Opportunities
For more information visit http://www.researchandmarkets.com/research/v6jdrd/alzheimers
Media Contact: Laura Wood, +353-1-481-1716, email@example.com
SOURCE Research and Markets